anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Every patient will be his/her own control. Conventional 24-hours Holter monitoring will be simulated using data obtained by the Pocket-ECG III® system in the first 24 hours, ignoring the registries of the rest of days. Two and Three 24-hours conventional Holter strategies will also be simulated analyzing data from first 24 hours and 1-2 additional days, respectively, chosen by means of a random number creation system which will identify the days of registry to be considered.
BACKGROUND: Anthracycline chemotherapy is highly effective in treating various cancers but is associated with significant cardiotoxicity. Chinese herbal compounds have shown promise in mitigating this adverse effect, warranting systematic evaluation for clinical applicability.
OBJECTIVE: This study seeks to systematically assess the effectiveness of Chinese herbal compounds in managing anthracycline-induced cardiotoxicity via meta-analysis. The objective is to establish an evidence-based framework for their clinical use in preventing and treating this condition.
METHODS: This study employed a systematic review and meta-analysis design. A comprehensive search strategy was implemented across multiple databases, including CNKI, VIP, PubMed, Embase, and the Cochrane Library, to identify relevant randomized controlled trials (RCTs). Data collection involved extracting information on the efficacy of Chinese herbal compounds in treating anthracycline-induced cardiotoxicity. The primary outcome measures included left ventricular ejection fraction (LVEF), serum levels of cardiac troponin I (cTnI), creatine kinase-MB (CK-MB), creatine kinase (CK), and ST-T abnormality. The risk of bias in these studies was assessed following Cochrane Handbook guidelines. Meta-analysis of outcome indicators was conducted utilizing RevMan 5.4.
RESULTS: A total of 10 RCTs involving 748 patients met the inclusion criteria. Findings indicate that Chinese herbal compounds significantly enhance left ventricular ejection fraction (LVEF) while reducing serum levels of cTnI, CK-MB, and CK. Additionally, the compounds demonstrate a significant improvement in ST-T abnormality.
CONCLUSIONS: Chinese herbal compounds exhibit promising potential in ameliorating anthracycline-induced cardiotoxicity. These findings underscore the potential utility of Chinese herbal medicine as an adjunctive therapy in managing this condition. Further research is warranted to explain the underlying mechanisms and optimize their clinical application.
A device is provided for treating inflammation, viral infection, and infectious disease conditions.  The device includes a sublingual delivery film, dissolvable powder, compressed tablet, or tincture, with an ACE2 receptor binding competitor and a CB2 receptor agonist that could include cannabichromene. A composition is also provided to treat inflammation, viral infection, or infectious disease. The composition includes an ACE2 receptor binding competitor and a CB2 receptor agonist. A method is also provided for treating inflammation, viral infection, or infectious disease, including applying a sublingual delivery film, dissolvable powder, compressed tablet, or tincture, with an ACE2 receptor binding competitor and a CB2 receptor agonist. A composition for treating a patient with inflammation, viral infection and/or infectious disease is also provided, including an ACE2 receptor binding competitor and a CB2 receptor agonist.
Despite the inflammatory nature of lung disease in CF, nitric oxide (NO) formation as well as the expression of NOS2 has been found to be decreased in CF airways. While the reasons for impaired airway NO formation remain incompletely understood, there is evidence that low NO formation contributes to lung pathophysiology in CF. Constitutive endogenous formation of Nitric oxide (NO) in airways is thought to play a role in neurotransmission, smooth muscle relaxation and bronchodilation. Previous animal experiments have shown that the addition of L-arginine, the precursor of enzymatic NO formation, resulted in a significantly greater relaxation of tracheas. There is also evidence that a single dose of inhaled L-arginine improves pulmonary function in CF. In this study we will assess the effect of L-arginine inhalation on lung function, nitric oxide formation, airway inflammation and bacterial infection in CF patients.
The invention describes a peptide vaccine which aims at cancers. Particularly, the invention provides isolated epitope peptides which derive from an SEMA5B gene and leads to CTL, and therefore the isolated epitope peptides are suitable for immunotherapy on cancers. Each peptide of the invention comprises an SEMA5B derived peptide and a modified form thereof, wherein one, two or a plurality of amino acids are substituted, missing, inserted or added as long as the modified forms have the necessary CTL induction capability of the original sequence. Furthermore the invention provides a polynucleotide for coding the peptides, and a drug composition comprising a random peptide or the polynucleotide as active reagents. The invention further provides an antigen presenting cell which is targeted to the peptides and an isolated CTL, and a method for inducing the antigen presenting cell or the CTL. Furthermore the invention provides a method for treating and/or preventing (such as preventing) cancer (tumor)(such as esophageal cancer, NSCLC, RCC and SCLC) and/or preventing cancer metastasis or reoccurrence after surgery, a method for inducing the CTL, and a method for inducing an anti-tumor immunity, wherein the peptides which derive from the SEMA5B, the polynucleotide for coding the peptides or the antigen presenting cell for presenting the peptides, or the drug composition are represented.
AIRSUPRA contains budesonide, an inhaled corticosteroid (ICS). Localized infections of the mouth and pharynx with Candida albicans have occurred in patients treated with ICS agents. Monitor patients periodically. When such an infection develops, it should be treated with appropriate local or systemic (i.e., oral) antifungal therapy while treatment with AIRSUPRA continues. In some cases, therapy with AIRSUPRA may need to be interrupted. Advise the patient to rinse his/her mouth with water, if available, without swallowing following administration of AIRSUPRA to help reduce the risk of oropharyngeal candidiasis.
Efficacy of Flector® Patch was demonstrated in two of four studies of patients with minor sprains, strains, and contusions. Patients were randomly assigned to treatment with the Flector® Patch, or a placebo patch identical to the Flector® Patch minus the active ingredient. In the first of these two studies, patients with ankle sprains were treated once daily for a week. In the second study, patients with sprains, strains and contusions were treated twice daily for up to two weeks. Pain was assessed over the period of treatment. Patients treated with the Flector® Patch experienced a greater reduction in pain as compared to patients randomized to placebo patch as evidenced by the responder curves presented below.
PURPOSE:To obtain a substance for inhibiting secretion of acid in the stomach useful as an antiulcer, having quality of higher activity than a conventional substance, by dissolving a water-soluble benzoate in mammal urine, adjusting it to a proper pH to give a precipitate containing the substance for inhibiting secretion of acid in the stomach. CONSTITUTION:A water-soluble benzoate (e.g., Na salt of benzoate, ammonium salt of benzoate, etc.) is dissolved in mammal urine, and adjusted to <=5pH, to give a precipitate containing benzoic acid and a substance for inhibiting secretion of acid in the stomach. Benzoic acid is removed from the precipitate by well-known method such as washing with an organic solvent, dialysis, etc., to give a highly active substance for inhibiting secretion of acid in the stomach. The substance is named urogastrone, considered to be a substance having >=300,000 molecular weight, containing a saccharide and protein, and occurs especially in pregnant mammal urine in a large amount. This substance has more improved yield and specific activity than a conventional substance, and this process is excellent as an industrial preparation.
The dimerization and Oligomerisation of protein are universal biology controlling mechanisms, influence the intracellular and extracellular protein of active cell membrane receptor, transcription factor, vesicle fused protein and other classes. We have had developed a kind of universal method for adjusting intracellular protein dimerization or oligomerization. In principle, by including cell or the organism of target protein with permeable, synthesis ligand processing, any two target protein can be induced to contact. Practice in order to demonstrate the invention, we induction of: (1) T cell receptor (TCR)-CD3 compound it

 The intracellular accumulation of the cytoplasmic tail of chain, so as to cause the transcription of signal transduction and reporter gene, (2) the same dimerization of the cytoplasmic tail of Fas receptor, it is spontaneous dead (stylized cell death) so as to cause cell-specific, and the different dimerization of (3) combined area DNA (Ga14) and transcription-activation area (VP16), so as to cause the direct transcription of reporter gene. In conjunction with the intracellular protein of our cell permeable, synthesis ligand adjusted, a possibility that new is provided for biological study and medicine, especially gene therapy. Our artificial receptors are imported using gene transfer technique, and the signal transduction pathway for leading to treat product and being overexpressed can be switched on or off by Orally active " dimer " or " removing dimer " respectively. Because the cell from different acceptors is endowed the approach for being overexpressed and treating the not difference treatment albumen matter of same disease, which is possible to be used as " universal medication ". They can also be regarded as to cell permeable, organic substituents in relation to also needing the treatment antisense agent or protein (such as ldl receptor or CFTR protein) of intravenous injection or cell inner expression.
1521596 Treating aquatic animals with medicinal agents WILDLIFE VACCINES INC 1 Oct 1976 [3 Oct 1975] 40759/76 Heading A5B Water-living animals (e.g. fish) are treated to administer a health and/or welfare enhancing agent such as a chemotherapeutant or a vaccine, by immersing them in an aqueous solution which is hyperosmotic relative to their body fluids, and then immersing them in an aqueous medium containing the said agent for long enough (e.g. 2-5 minutes) for an effective amount of said agent to be absorbed by the animal. Typical medicaments are vaccines e.g. inactivated Infections haematopoietic virus, Vibrio anguillarum bacterin, Aeromonas salmonicida bacterin and Enteric Redmouth bacterin; antimycotic agents, parasiticides, anthelmintics and antibiotics; and bovine serium albumin. The hyperosmotic solution may comprise sodium or potassium chloride and/or urea, together with other salts and buffering agents and dextrose. A suitable tonicity for the solution is 1200 mOsm of solute, the fish being immersed therein for 30 seconds to 3 minutes.
PURPOSE: To reproducibly produce a controlled releasing agent for releasing a useful medicine into an organic environment at a reproducible rate over a long period of time. CONSTITUTION: Diketeneacetal or divinyl ether (A) is condensed with a useful medicine (B) having two or more hydroxyl functional groups, e.g. an anthelmintic such as avermectin or milbemycin and a polyol monomer (C) such as 1,6- hexanediol or tetraethylene glycol in the presence of a poly(ortho-ester) bonding stabilizer or a polyacetal bonding stabilizer, e.g. carbonates, org. amine or magnesium oxide. At this time, the component B and the stabilizer are added to the component C, the resultant mixture is stirred until variation in log [dielectric constant] becomes practically constant and the component A is added to the mixture.  Condensation reaction is continued until the viscosity of poly(ortho-ester) or polyacetal is made so sufficiently high as to uniformly disperse the stabilizer and the objective useful medicine-contg. poly(ortho-ester) or polyacetal polymer causing penetration into an organism is produced.
Endometrial preparation will begin on the second day of the menstrual cycle with oral estradiol (E2) valerate at a dose of 2 mg twice daily. When the patient's endometrial thickness is ≥7 mm, vaginal progesterone administration will be initiated at a dose of 200 mg 3 times daily. On day 5 of the progesterone administration, blastocysts are thawed and transferred. For patients with endometrial thickness \<7 mm, patients continued oral E2 until the endometrium is ≥7 mm. On day 14 after blastocyst transfer, serum β-hCG levels are measured. Upon positive serum pregnancy testing, E2 and progesterone supplementation is continued for 8-10 weeks of gestation.
<P>PROBLEM TO BE SOLVED: To provide a method of cellular growth and a method of modification of characteristic of fibrin matrix regarding internal growth.  <P>SOLUTION: For the formation of a fibrin matrix, a fibrinogen comprising a selected fibrinogen variant or a fibrinogen rich or poor in selected fibrinogen variant is used. Especially, use of a high molecular weight (HMW) fibrinogen provides a fibrin having accelerated angiopoietic characteristic, and use of a low molecular weight (LMW and/or LMW') fibrinogen provides a fibrin having decelerated angiopoietic characteristic. A fibrin sealant based on HMW fibrinogen is used for burn wound because it promotes wound treatment or it inhibits cicatricial tissue. A fibrin sealant based on LMW or LMW' fibrinogen is useful, for example, after surgical operation because it inhibits adhesion and tumor growth.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Diagnosis of human parvovirus B19 infection is carried out using a serologically active epitope in the form of a synthetic peptide. The diagnostic method uses antibodies to regions localised in the 'left hand orf' or 'right hand orf' of the B19 virus. The synthetic peptide preferably corresponds to the 'right hand orf' epitope. It comprises at least a five amino acid sequence from a number of specified sequences, including: Phe-Ala-Lys-Ala -Val-Thy-Gln-Gln-Phe -Val-Glu-Phe-Tyr-Glu -Lys-Val-Thr-Gly -Thr-Asp-Leu -Glu-Leu-Ile-Gln -Ile-Leu-Lys-Asp -His-Tyr-Asn-Ile -Ser-Leu-Asp. A vaccine containing one or more of the peptides and a carrier is also claimed. USE/ADVANTAGE - B19 virus causes infection associated with erythema infectiosum. After developing erythema infectiosum (fifth disease), antibodies to B19 are found in the blood. B19 appears to be associated with polyarthritis, aplastic crisis, Schonlein-Henoch purpura, and embryo pathologies and non-immune hydrops foetalis. The antibodies and peptides are therefore useful for the study of the virus infection, for prevention by immunisation and for diagnosis of the disease.
First and second members are constructed to be disposed in an individual's body without adversely affecting the functioning of the individual's body. The first and second members may be illustratively an orthodontic bracket and an orthodontic pad. An armorphous alloy is disposed between or adjacent to the first and second members in a thin layer (e.g. three thousandths of an inch (0.003'')) and is bonded, as by brazing, to the first and second members. The alloy is provided with properties of not affecting the functioning of the individual's body adversely. The alloy preferably has eutectic properties and has properties of being ductile and corrosion resistant. The alloy is preferably a metallic glass in which the primary element may be palladium. The alloy may consist of palladium, nickel and silicon. The composition of the alloy is preferably as follows: -Element Approximate Percentage -Palladium Ninety percent (90%) -Nickel Four Percent (4%) -Silicon Six Percent (6%) -  The alloy is not dense so that a minimal amount of material has to be used to bond the first and second members. The alloy provides a stronger bond to the first and second members than the alloys of the prior art.
Risk Summary   
There are no data on the presence of levocetirizine in human milk, the effects on the breastfed infant, or the effects on milk production. However, cetirizine has been reported to be present in human breast milk. In mice and beagle dogs, studies indicated that cetirizine was excreted in milk [see Data]. When a drug is present in animal milk, it is likely the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for levocetirizine dihydrochloride and any potential adverse effects on the breastfed child from levocetirizine dihydrochloride or from the underlying maternal condition.   
Data   
Animal data   
Cetirizine was detected in the milk of mice. No adverse developmental effects on pups were seen when cetirizine was administered orally to dams during lactation at a dose that was approximately 25 times the MRHD in adults  [see Use in Specific Populations ( 8.1)].  Studies in beagle dogs indicated that approximately 3% of the dose of cetirizine was excreted in milk. The concentration of drug in animal milk does not necessarily predict the concentration of drug in human milk.
Meat analog made from soy protein concentrate that was removed phytic acid (dephytinization) contains 58Fe as ferrous sulfate. All participants will consume this test meal.
The present invention provides fragments of the plasmodium circumsporozoite protein according to SEQ ID No. 1, for example for use in malaria vaccines. The invention also provides nucleic acids encoding fragments of plasmodium circumsporozoite protein according to SEQ ID No. 1, compositions comprising fragments of plasmodium circumsporozoite protein according to SEQ ID No. 1 and antibodies binding fragments of plasmodium circumsporozoite protein according to SEQ ID No. 1. The antibodies according to the invention bind specifically to plasmodium falciparum sporozoites and are useful for the treatment and/or prevention of malaria.
PURPOSE:To obtain the title carrier having excellent antitumor activity and low toxicity, by preparing a partially deacetylated glycol chitin from chitin as a raw material and reacting it with 1-beta-carboxyethyl-5-fluorouracil. CONSTITUTION:Chitin of formula I (wherein n is 100 or larger) is treated with an alkali and then reacted with ethylene oxide to prepare a partially deacetylated glycol chitin of formula II (wherein R1 is H or COCH3; R2 is OH or OCH2CH2OH). Separately, 1-beta-carboxyethyl-5-fluorouracil is prepd. by reacting 5-fluorouracil of formula III with ethyl acrylate by addition reaction and then hydrolyzing the adduct. Then, a 5-fluorouracil carrier of formula V is obtd. by reacting a compd. of formula II with a compd. of formula IV. This carrier release 5-fluorouracil after it is incorporated into tumor cells as it is.
The invention discloses a recombinant low-virulent vaccine strain of chicken infectious bursal disease viruses (IBDV) and application thereof. In the invention, a major protective antigen gene VP2 of an epidemic superhigh virulent strain is cloned, the nucleotide of the gene VP2 is modified by mutation and then used for replacing a corresponding segment of a Gt genome of a low-virulent strain of the IBDV, so that the infectious clone of a recombinant genome of the IBDV is constructed, and the recombinant low-virulent vaccine strain is saved and identified by using an IBDV reverse genetic operation system. The microbial collection number of the vaccine strain is CGMCC No.3749. The recombinant low-virulent vaccine strain of the invention has high replicability, genetic stability and safety. The immune effect of the low-virulent vaccine strain of the invention is as good as that of the medium-virulent vaccine strain, but is superior to that of the low-virulent vaccine strain. The biological safety of the low-virulent vaccine strain of the invention is superior to that of the medium-virulent vaccine strain. As the vaccine strain, the recombinant low-virulent vaccine strain of the invention has the characteristics of high efficiency and low toxicity, is a good candidate vaccine strain and can be used for controlling chicken infectious bursal disease.
Exergames for rehabilitation of hemineglected stroke patients played with a haptic device on a computer. 5 sessions per week, 30-45 minutes per training for 3 weeks, with an intensity individually adjusted by the treating therapist according to the progress of the participating patient.
PURPOSE:To obtain the subject agent effective in extremely remarkably suppressing the metastasis of cancer cell and having low cytotoxicity, by using an N-substituted-1-deoxynojirimycin derivative as an active component. CONSTITUTION:The objective agent can be prepared by using a compound of formula (X is 3-5C hydrocarbon group; Y is O or S; R1 and R2 are H, lower alkyl or halogen) and forming the compound in the form of a drug by conventional method using conventional additives. It can be prepared in the form of capsule, tablet, granule, fine particles, powder, solution, suspension, etc. Dose: 100-3,000mg daily in 1-several divided doses. The compound of formula is e.g. N-(2-phenoxyethyl)-1-deoxynojirimycin.
BACKGROUND AND AIMS: Intermittent fasting is a nutritional strategy that focuses on when to eat, rather than what to eat. Although the effectiveness of intermittent fasting practices in many metabolic diseases is known, its effect on microbiota and its underlying mechanism has not yet been clarified. This study aimed to investigate the effect of Ramadan fasting, one of the intermittent fasting practices, on gut microbiota and fatty acid binding protein 4 (FABP4).
METHODS: The study involved 10 male volunteers, 6 of whom were overweight and 4 were obese. They fasted for an average of 14-15 hours daily from dawn to sunset during the 29-day Ramadan month between 23 March - 20 April 2023 and met the inclusion criteria. The participants' nutritional and physical activity status before and during Ramadan, as well as their anthropometric measurements before and after Ramadan, intestinal microbiota, transaminases, gamma-glutamyl transferase, C reactive protein, total cholesterol (C), high-density lipoprotein (HDL) C, low-density lipoprotein C, triglycerides (TG), and FABP4 levels, were evaluated within the scope of the study.
RESULTS: The study found a statistically significant increase in both alpha and beta diversity in the intestinal microbiota following Ramadan fasting (p<0.05). The F/B ratio, Firmicutes phylum, Clostridia class, Clostridiales order, and Ruminococcaceae family exhibited statistically significant decreases, while the Bacteroidetes and Proteobacteria phyla, Bacteroidia, Alphaproteobacteria, and Erysipelotrichi classes, Bacteroidales, Erysipelotrichales, and Actinomycetales orders, Erysipelotrichaceae family and Prevotella genus, demonstrated statistically significant increases (p<0.05). Participants who achieved an average weight loss of 2.3±0.99 kg at the end of Ramadan showed a significant increase in HDL-C and a significant decrease in TG levels (p<0.05). Although FABP4 levels decreased after fasting, this difference was not statistically significant (p>0.05).
CONCLUSION: Ramadan fasting induces weight loss, modifies gut microbiota, and improves blood lipid profile and FABP4 levels, suggesting the need for more extensive studies.